PD-L1 up-regulation restrains Th17 cell differentiation in STAT3 loss- and STAT1 gain-of-function patients by Zhang, Yuan et al.
Br ief Definit ive Repor t
The Rockefeller University Press 
J. Exp. Med. 2017 Vol. 214 No. 9 2523–2533
https://doi.org/10.1084/jem.20161427
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
2523
IntroductIon
Over the past several decades, increasing numbers of pa-
tients have been identified with inborn errors of cytokine 
receptors and downstream JAK-STAT signaling molecules 
that manifest with highly diverse immunologic and clinical 
phenotypes (Casanova et al., 2012). Patients with autoso-
mal-dominant, hyper-IgE syndrome have elevated serum IgE 
levels, eczema, and connective tissue disease, including intra-
cranial aneurysms and other vascular abnormalities (Fathi et 
al., 2011; Chandesris et al., 2012a). They display a particular 
susceptibility to skin and lung infection with Staphylococ-
cus aureus and Candida albicans (Casanova et al., 2012) and 
have impaired antigen-specific antibody responses (Leung et 
al., 1988; Avery et al., 2010; Meyer-Bahlburg et al., 2012). 
This syndrome is due to mutations in STAT3 primarily af-
fecting the DNA-binding, Src homology 2 (SH2), linker, or 
transactivation domains; most of which act in a dominant 
negative manner (STAT3 loss-of-function [LOF]) by destabi-
lizing the STAT3 protein (Chandesris et al., 2012b; Bocchini 
et al., 2016). Patients with hypermorphic, gain-of-function 
(GOF) mutations in STAT1 have autoimmune diseases and, 
similar to patients with STAT3 LOF, have an increased inci-
dence of vascular malformations, humoral immune defects, 
and susceptibility to fungal infections (Casanova et al., 2012; 
Romberg et al., 2013; Toubiana et al., 2016). Mutations lead-
ing to STAT1 GOF have been found predominantly in the 
coiled-coil domain or DNA-binding domain of STAT1 and 
lead to increased STAT1 phosphorylation in response to cy-
tokine stimulation at least in part by impairing nuclear de-
phosphorylation (Toubiana et al., 2016).
In addition to their clinical phenotypic similarities, pa-
tients with STAT3 LOF and STAT1 GOF also share simi-
lar cellular phenotypes. Reduced circulating Th17 (IL-17A+ 
and IL-17F+) cells and impaired Th17 differentiation are 
seen in patients with both STAT3 LOF and STAT1 GOF 
and underlie clinical susceptibility to chronic mucocutane-
ous candidiasis (CMC; de Beaucoudrey et al., 2008; Ma et 
al., 2008; Milner et al., 2008; Liu et al., 2011). These defects 
are thought to be due to either the direct requirement for 
STAT3-mediated transcription of retinoic acid receptor– 
related orphan receptor (ROR)-γt, the master transcription 
factor for Th17 differentiation (Yang et al., 2008), or inhibi-
tion of STAT3 function by enhanced STAT1 (Amadi-Obi et 
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al., 2007). In mouse models, inhibition of STAT3 signaling or 
IL-17 led to increased vascular aneurysm severity (Chandes-
ris et al., 2012a), raising the question of whether the vascular 
abnormalities seen in patients with STAT1 GOF and STAT3 
LOF could relate to their Th17 defect. Although vascular 
anomalies have not been described in patients with inherited 
mutations in IL17F, IL17RA, or IL17RC, the numbers of 
these patients reported is low and this could account for the 
lack of observed vascular issues (Puel et al., 2011; Ling et al., 
2015). Alternatively, deregulated TGF-β signaling, which has 
been reported in STAT3 LOF, could underlie these vascular 
defects (Lyons et al., 2017).
STAT family members have the ability to directly in-
teract and form homo- and heterodimers, and significant 
evidence exists for competition between STAT proteins for 
binding sites. For example, STAT3 and STAT5 compete for 
the Bcl6 and the Il17 loci (Yang et al., 2011; Oestreich et al., 
2012). Competition also exists between STAT1 and STAT3, 
including for binding on the Il21r and the Ifngr1 promot-
ers (Qing and Stark, 2004; Spolski and Leonard, 2008). The 
delicate balance between signaling of various STATs deter-
mines downstream effector fates. Thus, it is plausible that 
mutations leading to GOF or LOF of one STAT protein 
may disrupt that balance and have pleiotropic effects be-
cause of reciprocal LOF or GOF in other STAT proteins and 
their downstream targets.
Recently, the oral JAK 1/2 inhibitor ruxolitinib was 
used to successfully treat CMC and alopecia areata in pa-
tients with STAT1 GOF (Higgins et al., 2015; Mössner et 
al., 2016). In the case of STAT3 LOF, defining a treatment 
approach is more challenging because direct replacement of 
the deficient STAT3 protein is limited by the significant po-
tential for oncogenesis (Yu et al., 2009). However, a possi-
ble therapeutic opportunity in patients with this and other 
LOF mutations is in the use of inhibitors of downstream pro-
teins that are dysregulated.
Suppressors of cytokine signaling (SOCS) proteins 
are induced by cytokines and regulate the cellular response 
via a negative feedback loop (Yoshimura et al., 2007). 
STAT3-dependent up-regulation of SOCS3 impairs Th17 
cell differentiation via inhibition of IL-6 and IL-23 signaling, 
whereas STAT1-driven SOCS1 is required for Th17 differ-
entiation (Chen et al., 2006; Tanaka et al., 2008). Although 
naive T cells from patients with STAT3 LOF have reduced 
SOCS3 transcripts (Siegel et al., 2011; Chandesris et al., 
2012b), those patients paradoxically also have a decrease in 
Th17 cells (Milner et al., 2008). One possible explanation is 
that the decrease in SOCS3 leads to disinhibition of other cy-
tokine signaling pathways, such as IL-27 signaling via STAT1. 
IL-27 priming of naive cluster of differentiation (CD) 4+ T 
cells leads to up-regulation of programmed cell death protein 
ligand 1 (PD-L1) in a STAT1-dependent manner (Hirahara 
et al., 2012). Consistent with this, PD-L1 can be found ex 
vivo on naive CD4+ T cells in patients with STAT1 GOF 
(Romberg et al., 2013). PD-L1 delivers an inhibitory sig-
nal after T cell activation via its interactions with PD-1 and 
B7-1, and the PD-L1/PD-1 interaction has been shown in 
a mouse model to impair Th17 differentiation (Butte et al., 
2007; Hirahara et al., 2012).
We describe here a common cellular phenotype of 
STAT1 hyperphosphorylation in response to cytokine stim-
ulation in patients with STAT1 GOF and STAT3 LOF. 
We show that STAT1-dependent PD-L1 up-regulation is 
markedly enhanced in STAT3 LOF and STAT1 GOF lym-
phocytes compared with healthy donor cells. Both STAT1 
hyperphosphorylation and PD-L1 up-regulation are associ-
ated with significantly reduced SOCS3 protein expression, 
and overexpression of SOCS3 strongly inhibited phosphory-
lation of STAT1. Furthermore, defects in Th17 differentiation 
could be partially overcome via PD-L1 inhibition.
reSuLtS And dIScuSSIon
enhanced cytokine-induced phosphorylation of StAt1 in 
patients with StAt3 LoF is similar to that seen in StAt1 
GoF and is, in part, caused by decreased SocS3 expression
After stimulation for 15 min with IL-6, IL-21, IFN-γ (not 
depicted), or IL-27 (cytokines known to signal via STAT1 
and/or STAT3), the level of cytokine-induced STAT1 phos-
phorylation (pSTAT1) among CD3+ T cells was significantly 
increased in patients with STAT1 GOF and STAT3 LOF 
compared with healthy controls (HCs; Fig. 1 A, left). Consis-
tent with recently reported data (Tabellini et al., 2017), total 
STAT1 protein levels were also increased at baseline and after 
cytokine stimulation in some patients with STAT1 GOF 
compared with HCs (Fig. 1 B) potentially explaining some 
of the increased pSTAT1 in patients with STAT1 GOF. In 
contrast, only one patient with STAT3 LOF was identified 
with increased total STAT1. No difference was seen in the 
levels of cytokine-induced pSTAT3 (Fig.  1  A, right), con-
sistent with previous studies examining pSTAT3 in patients 
with STAT3 LOF and STAT1 GOF (Renner et al., 2008; 
Higgins et al., 2015; Zheng et al., 2015), suggesting regulation 
of pSTAT1 by a STAT3-dependent mechanism, but not nec-
essarily the reciprocal.
We next sought to explore the mechanism of 
STAT3-dependent regulation of pSTAT1. Naive CD4+ 
T cells from patients with STAT3 LOF and STAT1 GOF 
were found to have decreased SOCS3 transcripts compared 
with HCs after stimulation for 1 h with IL-6 and, to a lesser 
extent, IL-21 and IL-27, consistent with previous studies 
(Fig.  1 C; Siegel et al., 2011; Zheng et al., 2015). No sig-
nificant difference was found in SOCS1 mRNA levels at 
rest or after cytokine stimulation (Fig. 1 C), suggesting a tar-
geted effect of STAT3 signaling on SOCS3. This finding of 
decreased cytokine-induced SOCS3 was also confirmed at 
the protein level (Fig. 1 D). To determine whether SOCS3 
overexpression could correct the observed hyperphosphor-
ylation of STAT1, naive CD4+ T cells were transfected with 
a SOCS3–GFP construct or an empty GFP control vector. 
Overexpression of SOCS3 significantly decreased IL-27– 
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Figure 1. StAt3 LoF and StAt1 GoF cells have enhanced pStAt1 that is partially dependent on impaired induction of SocS3. (A) pSTAT1 (left) 
and pSTAT3 (right) in PBMCs after stimulation with IL-6, IL-21, or IL-27 for 15 min. (B) Total STAT1 in PBM CS before stimulation (left) and after cytokine 
stimulation (right) for 15 min. (C and D) SOCS3 and SOCS1 mRNA (C) and SOCS3 protein (D) levels in naive CD4 T cells after stimulation with IL-6, IL-21, 
or IL-27 for 1 h. (E and F) Naive (CD45RO−) CD4+ T cells were transfected with SOCS3–GFP or GFP–control or SOCS3–RNAi or scramble RNAi–control. 
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induced pSTAT1 in HCs and in patients with STAT3 LOF 
and STAT1 GOF (Fig. 1 E), with no change in total STAT1 
expression (not depicted). To further confirm that decreased 
SOCS3 results in dysregulated, cytokine-induced pSTAT1, 
we used SOCS3 RNAi to knock down SOCS3 expression 
in HC cells. As expected, IL-27-induced pSTAT1 was signifi-
cantly increased (Fig. 1 F).
IL-27–driven Pd-L1 is up-regulated on naive t cells in 
patients with StAt3 LoF and StAt1 GoF
To determine the effects of STAT1 hyperphosphorylation 
on downstream target genes, we examined the expression 
of PD-L1 in response to IL-27, which has previously been 
shown to up-regulate PD-L1 in a STAT1-dependent man-
ner (Hirahara et al., 2012). Basal PD-L1 expression was in-
creased in naive and memory CD4+ T cells from patients 
with STAT1 GOF (not depicted), consistent with previous 
studies (Romberg et al., 2013). Levels of PD-L1 were also 
significantly increased after IL-27 stimulation of naive CD4+ 
T cells from STAT3 LOF or STAT1 GOF, relative to that 
of HCs (Fig. 2 A). Treatment with a siRNA molecule tar-
geting STAT1 effectively reduced STAT1 expression levels 
(Fig. 2 B) and corrected that phenotype (Fig. 2 C). SOCS3 
overexpression resulted in significantly lower IL-27–induced 
PD-L1 in cells from patients with STAT3 LOF and STAT1 
GOF (Fig. 2 D). Conversely, SOCS3 silencing in HCs using 
RNAi resulted in increased PD-L1 levels (Fig.  2  E). Col-
lectively, these results demonstrate enhanced activity of the 
IL-27/STAT1 signaling pathway, at least in part, because of 
SOCS3 disinhibition, resulting in PD-L1 overexpression in 
STAT3 LOF and STAT1 GOF.
enhanced IL-27/StAt1/Pd-L1 pathway activation inhibits 
th17 differentiation in StAt3 LoF and StAt1 GoF
We next sought to determine whether the observed impair-
ment of Th17 differentiation in these patients could be ex-
plained by increased signaling via the IL-27/STAT1/PD-L1 
pathway. Naive CD4+ T cells from HCs and from patients 
with STAT3 LOF and STAT1 GOF were cultured with 
anti-CD3/CD28 under Th17- or non(Th0)-skewing con-
ditions. Decreased frequencies of CD45RO+IL-17A+ and 
CD45RO+IL-17F+ T cells and decreased IL-17A protein 
levels were found under Th17-skewing conditions in STAT3 
LOF and STAT1 GOF compared with HCs (Fig. 3, A–D). 
Both PD-1 and PD-L1 levels were increased in STAT3 
LOF cells cultured under Th17 conditions, despite being 
unchanged or decreased in HC cells (Fig. 3, E and F). The 
addition of an anti-human PD-L1 inhibitory mAb partially 
restored IL-17A protein and transcript levels in STAT3 LOF 
and STAT1 GOF (Fig.  3, A–D and G). A modest increase 
above baseline IL-17A+ cells was also observed in most HCs 
under PD-L1 blockade (Fig. 3 C), suggesting a greater neg-
ative effect of increased PD-L1 in patients’ cells where there 
are also other pathway disruptions as compared with HCs. 
IL-17F was not rescued by PD-L1 blockade (Fig.  3, A, D, 
and G). Additionally, PD-L1 blockade restored transcription 
of RORC, which encodes for the Th17 master transcription 
factor ROR-γt (Fig. 3 G).
Finally, to confirm that finding in vivo, Stat3-mut mice 
(Steward-Tharp et al., 2014) were immunized with OVA/
CFA, and Th17 cytokine production was measured in cells 
isolated from LNs 1 wk later. As expected, there was a de-
creased frequency of CD4+CD44+IL-17A+ memory T cells 
from Stat3-mut mice compared with WT. Crossing with 
PD-1 KO mice to generate double-mutant (DM) mice led 
to restoration of IL-17A frequencies in WT mice (Fig. 4, A 
and B). Increased PD-L1 protein (Fig.  4 C) and decreased 
Socs3 mRNA levels (Fig. 4 D) induced by IL-6 were seen 
in Stat3-mut mice, with normalization of both PD-L1 and 
Socs3 levels in DM mice. To see whether that correlated with 
in vivo suppression of C. albicans, we used a model of oro-
pharyngeal candidiasis (OPC) with measurement of tongue 
fungal load (in CFU/g) as a marker of fungal burden. As ex-
pected, the Stat3-mut mouse had a significantly greater fungal 
burden than the WT mouse had, with a lower frequency of 
CD4+CD44+IL-17A+ draining LN cells (Fig. 4 E), indicating 
susceptibility to OPC. Although a partial rescue in the fre-
quency of IL-17A+ cells was observed in DM mice, it was in-
sufficient to confer protection from OPC (Fig. 4 E). This may 
be because CD4+ T cells are not the sole source of protective 
IL-17 required for mucosal anti-Candida immunity in mice 
(Gladiator et al., 2013; Conti et al., 2014). As such, rescue of 
CD4+ IL-17 production would not necessarily be expected 
to lead to alteration in the fungal burden.
Collectively, these data demonstrate a STAT1 GOF 
phenotype in patients with either STAT1 GOF or STAT3 
LOF and illustrate how seemingly disparate molecular de-
fects, each of which results in an alteration in the balance 
between JAK-STAT signaling molecules, can lead to simi-
lar downstream defects. Reciprocal effects exist: enhanced 
STAT1 activity interferes with STAT3 function, but muta-
tions in STAT3 seem to interfere with appropriate control 
of STAT1. The dysregulated STAT1 signal enables enhanced 
IL-27–mediated up-regulation of PD-LI, which is associated 
with impaired Th17 differentiation and may contribute to the 
shared phenotype of susceptibility to CMC observed in both 
cohorts. Additional mechanisms in STAT1 GOF, including 
reduced transcription of STAT3-dependent Th17 gene tran-
scription because of reduced histone acetylation, may also 
contribute to the CMC phenotype (Zheng et al., 2015).
IL-27 was added 5 h after transfection, and pSTAT1 levels were analyzed 18–24 h later. One-way ANO VA (A–D) and paired and Student’s t tests (E and F) 
were performed. *, P < 0.05; **, P < 0.01. Data are representative of three independent experiments, unless otherwise indicated on the graph; graphs show 
means ± SEM. MFI, mean fluorescence intensity.
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Intriguingly, the impairment in Th17 differentiation 
could be partially overcome by treatment with a PD-L1 in-
hibitor, with restoration of RORC transcription and increase 
in IL-17A, but not IL-17F, expression. Differential regula-
tion of IL-17A and IL-17F has been noted previously, with 
a greater dependence of IL-17F on prostaglandin E2/STAT3 
and IL-17A on PI3K/mTOR/NFAT (Gomez-Rodriguez et 
al., 2009; Melton et al., 2013). In addition, enhanced chro-
matin accessibility of the IL-17A compared with the IL-17F 
locus has been noted in a primary human Th17 cell line, 
which could explain enhanced restoration of IL-17A (Ada-
mik et al., 2013). In mice, IL-17A deficiency leads to suscep-
tibility to both CMC and invasive candidiasis and S. aureus, 
whereas, in contrast, IL-17F has been found to be redun-
dant (Ishigame et al., 2009; Saijo et al., 2010). The relative 
importance of IL-17A compared with IL-17F in humans (as 
reviewed in Cypowyj et al., 2012) has not been clearly estab-
lished. In humans, patients with IL-17RA deficiency (Puel et 
al., 2011), IL-17RC deficiency (Ling et al., 2015), and IL-17F 
deficiency (Puel et al., 2011) have all been identified as having 
CMC. However, each of these defects impairs the cellular re-
sponse to both IL-17A and IL-17F homo- and heterodimers. 
Intriguingly, in the kindred with autosomal-dominant IL17F 
mutations, two mutation-carrying family members were as-
ymptomatic, raising the possibility that IL17F in humans, 
similar to that found in mice, may be dispensable (Puel et 
al., 2011). Because humans with IL17A mutations have not 
yet been identified, the relative importance of each individual 
cytokine in host defense is not yet clearly established.
Importantly, despite the in vitro restoration in primary 
human CD4+ T cells of RORC and IL17A in the setting of 
PD-L1 blockade, PD-1 blockade was not sufficient in our 
model to protect Stat3-mut mice against OPC. Important 
differences exist between mouse and human host defenses to 
Candida, including an important role for innate immune cells, 
which may explain the result. Certainly, the in vitro findings 
in humans provide the basis for further studies into the use 
of immune checkpoint inhibitors targeting PD-1/PD-L1 for 
the treatment of infectious phenotypes associated with IL17 
defects (Webster, 2014). Additionally, there is the potential to 
restore other lineages that are restrained by PD-1/PD-L1 and 
are found to be defective in these diseases. The broader con-
cept of inhibiting a molecule that is increased because of the 
inherited LOF of another protein (or the reciprocal), holds 
promise as a novel therapeutic approach to be explored in 
patients with mutations in cytokine signaling pathways.
Figure 2. High pStAt1 drives increased Pd-L1 expression in StAt3 LoF and StAt1 GoF cells. (A) PD-L1 expression on naive (CD45RO−) T cells 
from HCs and patients after 24 h of stimulation with IL-27. Naive (CD45RO−) CD4+ T cells were transfected with STAT1 RNAi or scramble RNAi (B and C), 
SOCS3-GFP or GFP-control (D), or SOCS3 RNAi or scramble RNAi (E). (B) STAT1 expression after transfection with STAT1 RNAi. (C–E) PD-L1 expression 41 h 
after IL-27 stimulation. One-way ANO VA (A) and paired Student’s t tests (C–E) were performed. *, P < 0.05; **, P < 0.01. Data are representative of three 
independent experiments unless otherwise indicated on the graph; graphs show means ± SEM. MFI, mean fluorescence intensity.
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MAterIALS And MetHodS
Human subjects and clinical studies
All patients or their guardians provided informed consent 
under approved protocols of the National Institute of Allergy 
and Infectious Diseases Institutional Review Board (10-I-
0148 and 00-I-0159), as well as the guidelines in the Decla-
ration of Helsinki. Subjects with STAT3 LOF had mutations 
in the SH2 domain (n = 6), DNA binding domain (n = 8), 
and transactivation domain (n = 1) and ranged from 11 to 
47 yr old; five were male. Subjects with STAT1 GOF had 
mutations in the coiled-coil domain (n = 5), DNA-binding 
domain (n = 4), and SH2 domain (n = 1) and ranged from 4 
to 60 yr old; 3 were male. Additional genotype and phenotype 
information is included in Table S1. Blood from HCs was ob-
tained under Institutional Review Board–approved protocols.
Flow cytometry
PBMCs were isolated from whole blood by Ficoll-Hypaque 
gradient centrifugation and washed with FACS buffer. Events 
were collected on an LSRFortessa with Diva 6.1.3 software 
(BD Biosciences) and analyzed with FlowJo 10 software 
(Tree Star). All plots are gated on live, singlet, CD3+ lympho-
cytes. All values used for analyzing proportionate responses 
are background subtracted.
StAt phosphorylation
To assay STAT1 and STAT3 phosphorylation, PBMCs were 
incubated at 37°C for 1 h in serum-free RPMI 1640 and then 
stimulated for 15 min with media alone, IL-6 (100 ng/ml; 
PeproTech), IFN-γ (2,000 U/ml; PeproTech), IL-21 (100 
ng/ml; PeproTech), or IL-27 (50 ng/ml; R&D Systems) be-
fore being fixed with paraformaldehyde and permeabilized 
in methanol. Cells were stained with CD3 Alexa Fluor 700, 
pSTAT1 (pY701) AF488, pSTAT3 (pY705) PE, and STAT1 
FITC (all BD Biosciences).
real-time Pcr
To assay SOCS1 and SOCS3/Socs3 up-regulation in re-
sponse to cytokine stimulation, naive CD4 T cells were stim-
ulated with or without IL-6 (100 ng/ml; PeproTech), IL-21 
(100 ng/ml; PeproTech), or IL-27 (50 ng/ml, R&D Systems) 
for 1 h, as indicated in the text and figures. Cells were then 
washed and pelleted. Total RNA was extracted from PBMCs 
with the RNeasy Mini kit (QIA GEN). For real-time PCR, 
1 µg of total RNA was reverse-transcribed (Thermo Fisher 
Scientific), and the resulting cDNA was amplified by PCR 
with the ABI 7500 Sequencer and TaqMan expression assays 
(Thermo Fisher Scientific). 18S was used as a normalization 
control. The data were analyzed with the 2−▵▵Ct method, and 
results are expressed as mean fold induction.
SocS3 flow cytometry
Human, naïve, CD4+ T cells isolated from PBMC were stim-
ulated with IL-6 (100 ng/ml; PeproTech), IL-21 (100 ng/ml; 
PeproTech), or IL-27 (50 ng/ml; R&D Systems) for 90 min 
in RPMI 1640 plus 10% FBS. Cells were then fixed and per-
meabilized with Cytofix/Cytoperm (BD Biosciences), per 
the manufacturer’s protocol, then stained with anti-SOCS3 
antibodies and DyLight 488 Anti-Mouse IgG (Abcam).
Pd-L1 induction
PBMCs were incubated at 150,000 cells/well in 96-well, 
round-bottom plates for 24 h at 37°C and 5% CO2 in the 
presence or absence of IL-27 (50 ng/ml; R&D Systems) or 
IFN-γ (100 ng/ml; R&D Systems). Cells were harvested and 
stained with Live/Dead Fixable Aqua viability dye (Thermo 
Fisher Scientific), CD3 AF700, CD4 PE-Cy7, CD27 PE-
Cy5, CD45RO PE-Texas Red (BD Biosciences), and 
PD-L1 PE (BioLegend). Median fluorescence intensity of 
PD-L1 expression was assessed in the naive lymphocyte gate 
(CD3+CD4+CD27+CD45RO−).
SocS3 transfection
PBMCs were transfected with either GFP control (Lonza) 
or SOCS3–GFP construct (OriGene) using Amaxa Human 
T cell Nucleofection kit (Lonza) per the manufacturer’s pro-
tocol, with the Amaxa nucleofection program U-014. Cells 
were stimulated with IL-27 (20 ng/ml; R&D Systems) after 
allowing cells to rest for 5–7  h after transfection. STAT1 
phosphorylation (24  h stimulation) and PD-L1 expression 
(41 h stimulation) were assessed in live CD3+CD4+ lympho-
cytes as described above.
sirnA transfection
PBMCs were transfected with 30 pM STAT1 or SOCS3 
siRNA (Thermo Fisher Scientific) using Amaxa Human T 
cell Nucleofection kit (Lonza) per the manufacturers’ proto-
cols. Control cells were transfected with 30 pM nonspecific, 
scrambled siRNA. Cells were stimulated with IL-27 (50 ng/ml; 
R&D Systems) after allowing cells to rest for 5–7  h after 
transfection. Cells were harvested and stained for pSTAT1 
and PD-L1 as per above.
th17 cell differentiation and cytokine analyses
Naive CD4+ T cells were isolated from PBMCs using neg-
ative-selection, magnetic-activated, cell-sorting microbeads 
Figure 3. th17 cytokine production is impaired in StAt3 LoF and StAt1 GoF t cells, and IL-17A can be partially restored by blocking Pd-L1. 
Naive CD4+ T cells from HCs and patients were cultured for 6 d under Th0 or Th17 conditions in the presence of PD-L1 blocking antibody (anti-PD-L1) 
or control IgG. Expression of IL-17A and IL-17F (A–D), PD-1 (E), and PD-L1 (F) were analyzed. (G) IL17A, IL17F, and RORC mRNA levels in cells are shown. 
One-way ANO VA between genotypes (C–G) and paired Student’s t tests (B) were performed. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data are representative 
of three independent experiments. Graphs show means ± SEM.
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(Miltenyi Biotec) per manufacturer’s protocol. Purity was 
>95% in all samples run. For T cell differentiation, cells were 
stimulated at 100,000 cells/well in 96-well, flat-bottom plates 
that had been coated with anti-CD3 (10 µg/ml, OKT3; 
eBioscience) antibodies. The cells were cultured in X-VIVO 
15 medium (Lonza) at 37°C and 5% CO2 for 6 d in the 
presence of soluble anti-CD28 (0.5 μg/ml). For Th17, anti–
IFN-γ (10 μg/ml; BD Biosciences), IL-23 (100 ng/ml; R&D 
Systems), IL-1β (10 ng/ml; PeproTech), and IL-6 (20 ng/ml; 
PeproTech) were added in the culture. For Th0, 100 U/ml 
IL-2 (R&D Systems) was added. In certain experiments, cells 
were pretreated with 10 μg/ml of anti-human PD-L1 mAb 
(AMP-714; kindly supplied by Amplimmune, Inc., AstraZen-
eca) or UltraLEAF-purified human-isotype control IgG4 
antibody (BioLegend). ELI SA analysis was performed for IL-
17A (R&D Systems) secretion on d 6 for expanded T cells 
in culture. On d 6, the cells were stimulated with 20 ng/ml 
PMA and 1 µM ionomycin for 5 h. 10 µg/ml brefeldin A 
was added after 2.5  h. Cells were then fixed and permea-
bilized with Cytofix/Cytoperm per the manufacturer’s pro-
tocol and stained with Live/Dead Fixable Aqua dye, CD3 
AF700, CD4 PE-Cy7, IL-17F AF488, IFN-γ fluorescein 
v450 (BD Biosciences), CD45RO ECD (Beckman Coulter), 
and IL-17A APC (eBioscience).
Stat3-mut and Pd-1 Ko mouse
All animal work was performed under an Animal Care and 
Use Committee–approved protocol. All mice were derived 
from a C57BL/6 background. Littermates are obtained by 
breeding from the original sources, and no outside WT mice 
were used as controls or for breeding. The Stat3-mut mouse 
was a gift from John O’Shea (NIA MS, NIH, Bethesda, MD). 
Figure 4. Stat3-mut mice have impaired IL-17A production that can be restored in Stat3-mut/Pd-1 Ko (dM) mice. (A and B) IFN-γ and IL-17A 
expression by CD4+CD44+ draining LN cells from WT, Stat3-mut, PD-1 KO, and DM mice was analyzed 1 wk after OVA/CFA immunization. (C) PD-L1 expres-
sion on CD4+CD44− T cells after 24 h of stimulation with IL-6. (D) Socs3 mRNA levels in CD4+CD44− T cells before and after stimulation with IL-6 for 1 h. 
(E) Fungal load in the tongues and the percentage of CD4+CD44+IL-17A+ cells in cervical LN in Candida-infected mice was determined at d 3 postinfection 
(pi). One-way ANO VA was performed (B–E). *, P < 0.05; **, P < 0.01. Graphs show means ± SEM. (A-D) WT, n = 5; hyper-IgE syndrome, n = 3; DM, n = 3; PD-1 
KO, n = 2. (E) Data were combined from three independent experiments, n = 5–14 mice/group.
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The mouse has a single aa deletion (ΔV463) in the STAT3 
DNA-binding domain to mimic the heterozygous mutation 
seen in patients (Steward-Tharp et al., 2014). PD-1 KO mouse 
is a gift from Daniel Barber (NIA ID, NIH, Bethesda, MD). 
For OVA/CFA-induced Th17, mice were injected with 25 µg 
OVA plus 1:1 CFA per site s.c. on the back (four sites per 
mouse). After 1 wk, cells were harvested from draining LNs 
and were cultured in 1 ml RPMI 1640 with 10% FBS, 2-ME, 
20 ng/ml PMA, and 1 µM ionomycin in a 48-well plate. After 
1 h of incubation, 5 µg/ml brefeldin A was added to the cul-
ture, and incubation was continued for another 5–6 h. Cells 
were fixed, permeabilized, and stained with antibodies using 
the Cytofix/Cytoperm kit (BD Biosciences), according to the 
manufacturer’s protocol, and flow cytometry was performed.
Mouse model of oPc and quantification of fungal load
C. albicans strain SC5314 was grown in yeast, peptone, and 
dextrose medium (containing penicillin and streptomycin) 
by incubation in a shaking incubator at 30°C. To induce 
OPC in mice, mice were sublingually infected, as previ-
ously described (Solis and Filler, 2012; Break et al., 2015). In 
brief, mice were sedated with a ketamine/xylazine mixture 
and cotton swabs were saturated in 107/ml C. albicans. A 
swab was placed securely under the tongues of mice for 90 
min, with repeated administrations of ketamine/xylazine as 
needed. To determine the fungal load in the tongues of mice 
on d 3 after infection, tongues were weighed, homogenized 
with an Omni tissue homogenizer, and the entire tongue was 
plated on yeast, peptone, and dextrose agar plates contain-
ing penicillin and streptomycin. The plates were incubated 
at 37°C for 24–48  h and the CFUs were counted. If no 
colonies were counted, then a value of zero was assigned. 
PBMCs from cervical LN were isolated on d 3 after infec-
tion and were treated with PMA/ionomycin in the presence 
of brefeldin A for 5 h. Intracellular IL-17A in CD4+CD44+ 
cells was measured by flow cytometry.
Statistics
Two-group comparisons of normal data were made using 
the Student’s t test, and comparisons of nonnormal data were 
made with the Mann–Whitney U test. Multiple-group com-
parisons used ANO VA (Prism; GraphPad Software). The sta-
tistical significance level adopted was P < 0.05.
online supplemental material
Table S1 provides genotype and phenotype information on 
the patients in the study.
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